Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia of Alzheimer Type Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

NCT01148498
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
solanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Nov 14, 2026, 9:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Genetic Studies in Familial Dementia

NCT04680013
View directory record Official record
Conditions
Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
4,884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Nov 14, 2026, 9:57 PM EST
Terminated Phase 3 Interventional

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

NCT00380276
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MPC-7869
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
84
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Nov 14, 2026, 9:57 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

NCT03030105
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Nov 14, 2026, 9:57 PM EST
Completed Phase 2 Interventional Results available

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

NCT02185053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CPC-201
Drug
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Industry
Eligibility
50 Years to 79 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Nov 14, 2026, 9:57 PM EST
Completed Phase 2 Interventional

Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill

NCT06597058
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MAR
Drug
Lead sponsor
Noah Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Scottsdale, Arizona • Huntington Beach, California • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 14, 2026, 9:57 PM EST
Completed Phase 2 Interventional

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT01266525
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
SAR110894, placebo (for SAR110894), Donepezil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Nov 14, 2026, 9:57 PM EST
Terminated Phase 3 Interventional Results available

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT04408755
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Nov 14, 2026, 9:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Persons With Dementia and Their Extended Family Caregivers

NCT04863859
View directory record Official record
Conditions
Dementia, Dementia Alzheimers, Neuro-Degenerative Disease, Dementia of Alzheimer Type, Dementia Severe
Interventions
Not listed
Lead sponsor
Karen Roberto
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 14, 2026, 9:57 PM EST
Not listed Not applicable Interventional

REACH Hope Intervention for Dementia and TBI Caregivers

NCT04969796
View directory record Official record
Conditions
Dementia, Mixed, Dementia of Alzheimer Type, TBI (Traumatic Brain Injury)
Interventions
REACH Hope
Other
Lead sponsor
Memphis VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Nov 14, 2026, 9:57 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rural Dementia Caregiver Project

NCT04428112
View directory record Official record
Conditions
Depression, Stress, Psychological, Self Efficacy, Loneliness, Social Isolation, Health Care Utilization, Dementia, Dementia Alzheimers, Dementia of Alzheimer Type, Dementia, Vascular, Dementia Frontal, Dementia, Lewy Body, Dementia, Mixed, Dementia in Parkinsons Disease, Dementia, HIV, Dementia Frontotemporal, Dementia, Multi-Infarct
Interventions
Building Better Caregivers Workshop, Attention Control
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Nov 14, 2026, 9:57 PM EST
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 14, 2026, 9:57 PM EST
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Nov 14, 2026, 9:57 PM EST
Recruiting Not applicable Interventional

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

NCT06377033
View directory record Official record
Conditions
Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy Non-ischemic, Thoracic Aortic Aneurysm
Interventions
Behavioral nudge
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 14, 2026, 9:57 PM EST
Completed Phase 2 Interventional Results available

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

NCT01083316
View directory record Official record
Conditions
Amyloidosis
Interventions
Bortezomib, Dexamethasone, Melphalan
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Nov 14, 2026, 9:57 PM EST
Active, not recruiting Not applicable Interventional

Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies

NCT04699786
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
Arm A , Arm B, Arm C, & Arm D
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 14, 2026, 9:57 PM EST
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 14, 2026, 9:57 PM EST
Completed Not applicable Interventional

Telehealth-enabled Integrated Palliative Care for People With Dementia

NCT05524181
View directory record Official record
Conditions
Dementia of Alzheimer Type, Alzheimer Disease, Frontotemporal Degeneration, Lewy Body Dementia, Vascular Cognitive Impairment, Vascular Dementia, Mixed Dementia
Interventions
Telehealth Integrated Primary Care (TIPC)
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Nov 14, 2026, 9:57 PM EST
Completed Phase 3 Interventional

Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT00104013
View directory record Official record
Conditions
Alzheimer Disease
Interventions
xaliproden (SR57746A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
32
States / cities
Mesa, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Nov 14, 2026, 9:57 PM EST
Completed Not applicable Interventional Results available

Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)

NCT03160027
View directory record Official record
Conditions
Dementia, Alzheimer Type
Interventions
Vielight Neuro Gamma
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Nov 14, 2026, 9:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Studies of Brain and Body Interaction

NCT03672266
View directory record Official record
Conditions
Autistic Disorders Spectrum, Adhd, Asperger Syndrome, Alzheimer Disease, Parkinson, Tremor Essential, Dementia, Alzheimer Type, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia With Lewy Bodies, Dementia Frontal
Interventions
Not listed
Lead sponsor
Rutgers University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 14, 2026, 9:57 PM EST
Completed Phase 4 Interventional

A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

NCT00208819
View directory record Official record
Conditions
Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia
Interventions
risperidone, quetiapine, olanzapine, divalproex
Drug
Lead sponsor
Emory University
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Nov 14, 2026, 9:57 PM EST
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02442765
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
111
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Nov 14, 2026, 9:57 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Nov 14, 2026, 9:57 PM EST